Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 12, 2025
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile -
Read more at globenewswire.comNASDAQ:DRTSW (6/26/2025, 1:48:19 PM)
0.2498
0 (-0.04%)
NASDAQ:DRTS (6/26/2025, 2:06:32 PM)
3.07
+0.07 (+2.33%)
Find more stocks in the Stock Screener
